Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Status:
RECRUITING
Trial end date:
2029-06-09
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).